01:56 PM EST, 03/03/2025 (MT Newswires) -- Extendicare ( EXETF ) delivered a higher-than-forecast fourth quarter, reflecting many of the same themes that supported strong operational and financial performance over the course of 2024, writes BMO.

Analyst Tom Callaghan notes that top of the list was volume growth within the home health segment, where he expects another year of impressive growth in 2025 as the company continues to advance its tilt towards higher margin service segments.

Target price raised to $13.50 (+$2.50). Maintain Market Perform.

Price: 12.56, Change: +0.15, Percent Change: +1.21